VYXEOS LIPOSOMAL 44MG/100 MG INF PLV CSL 1

What is the maximum co-payment for VYXEOS LIPOSOMAL?

If the insurance company contributes, the maximum co-payment is 20 572,09 Kč. The maximum pharmacy price is 133 619,17 Kč. A pharmacy may provide the medicine for a lower price, but not for a higher price.

Does the medicine have reimbursement from public health insurance?

A medicine whose use is, in the public interest, appropriate to concentrate in specialized facilities pursuant to Section 15(10) of the Public Health Insurance Act. The medicine is reimbursed as ZÚLP and only from a facility that has a contract with the health insurer.

Does VYXEOS LIPOSOMAL have a counted co-payment set?

No, this medicine has no counted co-payment.

How much does the insurance company pay for one dispensed reimbursed pack?

113 047,08 Kč.

Does the insurance company pay a higher amount in some cases?

No, the medicine has no increased reimbursement.

Does the medicine have an indication restriction?

Přípravek je hrazen v léčbě dospělých pacientů ve věku od 60 let s nově diagnostikovanou akutní myeloidní leukémií související s léčbou nebo se změnami souvisejícími s myelodysplazií. Ze zdravotního pojištění jsou hrazeny nejvýše dva cykly indukční fáze a (v případě dosažení kompletní remise, s úplnou či neúplnou úpravou neutrofilů či trombocytů v krevním obrazu) nejvýše dva cykly konsolidační fáze léčby.

Is it available without a medical prescription?

No, the medicine cannot be obtained without a prescription.

Which medical specialist may prescribe VYXEOS LIPOSOMAL?

Prescription is not conditional on a medical specialization.

What is the composition of VYXEOS LIPOSOMAL?

Daunorubicin (44 mg), cytarabin (100 mg), neznámá látka s kódem 19143, neznámá látka s kódem 3745, cholesterol, kuprum(ii)-glukonát, trolamin, sacharosa. More information about the composition can be found in the SPC, section 6.1.